Compound 2 was inactive as a GLP-1R agonist in the unpotentiated cAMP screening assay (SA), which did not include BETP, but demonstrated a 70% effect at 20 M in the presence of BETP (Fig
Deficiencies in imprinted genes, such as MKRN3, MAGEL2, and/or NDN, are not enough on their own to cause the full range of symptoms seen in individuals with PWS
What You Can Do: Explore Other Medications: There are several weight loss medications and supplements that could complement semaglutide or act as an alternative if needed
The search strategy included combinations of the following keywords: GLP-1 receptor agonists, GLP-1 RA, gut microbiota, microbiome, short-chain fatty acids, bile acids, intestinal barrier, inflammation, and interindividual variability